Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Receivables - Net (2021 - 2025)

Historic Receivables - Net for BridgeBio Pharma (BBIO) over the last 4 years, with Q3 2025 value amounting to $116.5 million.

  • BridgeBio Pharma's Receivables - Net changed N/A to $116.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $116.5 million, marking a year-over-year change of. This contributed to the annual value of $4.7 million for FY2024, which is 16967.45% up from last year.
  • As of Q3 2025, BridgeBio Pharma's Receivables - Net stood at $116.5 million.
  • BridgeBio Pharma's Receivables - Net's 5-year high stood at $116.5 million during Q3 2025, with a 5-year trough of $1.2 million in Q2 2021.
  • In the last 4 years, BridgeBio Pharma's Receivables - Net had a median value of $40.8 million in 2024 and averaged $52.7 million.
  • Data for BridgeBio Pharma's Receivables - Net shows a peak YoY increase of 16967.45% (in 2024) and a maximum YoY decrease of 16967.45% (in 2024) over the last 5 years.
  • BridgeBio Pharma's Receivables - Net (Quarter) stood at $1.2 million in 2021, then soared by 44.35% to $1.8 million in 2023, then skyrocketed by 169.67% to $4.7 million in 2024, then soared by 2367.56% to $116.5 million in 2025.
  • Its Receivables - Net stands at $116.5 million for Q3 2025, versus $76.9 million for Q2 2025 and $115.3 million for Q1 2025.